2011-2190. Office of the Director, National Institutes of Health; Notice of Meeting  

  • Start Preamble

    Pursuant to section 10(a) of the Federal Advisory Committee Act, as amended (5 U.S.C. App.), notice is hereby given of a meeting of the Scientific Management Review Board.

    The NIH Reform Act of 2006 (Pub. L. 109-482) provides organizational authorities to HHS and NIH officials to: (1) Establish or abolish national research institutes; (2) reorganize the offices within the Office of the Director, NIH including adding, removing, or transferring the functions of such offices or establishing or terminating such offices; and (3) reorganize, divisions, centers, or other administrative units within an NIH national research institute or national center including adding, removing, or transferring the functions of such units, or establishing or terminating such units. The purpose of the Scientific Management Review Board (also referred to as SMRB or Board) is to advise appropriate HHS and NIH officials on the use of these organizational authorities and identify the reasons underlying the recommendations.

    The meeting will be open to the public, with attendance limited to space available. Individuals who plan to attend and need special assistance, such as sign language interpretation or other reasonable accommodations, should notify the Contact Person listed below in advance of the meeting.

    Name of Committee: Scientific Management Review Board.

    Date: February 23, 2011.

    Time: 11:30 a.m. to 1:30 p.m.

    Agenda: Presentation and discussion will focus on NIH activities related to the Board's recommendations to create a new center for advancing translational medicine and therapeutics development. As requested by the Board in its Report on Translational Medicine and Therapeutics, NIH will provide an update on the proposed creation of a new center and its evaluation of the impact of such a center on other relevant extant programs at NIH, including the National Center for Research Resources. The Board will also discuss next steps regarding future SMRB activities. Time will be allotted on the agenda for public comment. To sign up for public comment, please submit your name and affiliation to the contact person listed below by February 22, 2011. Sign up will be restricted to one sign up per e-mail. In the event that time does not allow for all those interested to present oral comments, anyone may file written comments using the contact person address below.

    The toll-free number to participate in the teleconference is 1-800-779-1545. Indicate to the conference operator that your Participant pass code is “NIH'.

    Place: National Institutes of Health, Office of the Director, NIH, Office of Science Policy, 6705 Rockledge Drive, Suite 750, Bethesda, MD 20892, (Telephone Conference Call)

    Contact Person: Lyric Jorgenson, Office of Science Policy, Office of the Director, NIH, National Institutes of Health, 6705 Rockledge Drive, Suite 750, Bethesda, MD 20892, smrb@mail.nih.gov, (301) 496-6837.

    Any interested person may file written comments with the committee by forwarding the statement to the Contact Person listed on this notice. The statement should include the name, address, telephone number and when applicable, the business or professional affiliation of the interested person.

    The draft meeting agenda, meeting materials, dial-in information, and other information about the SMRB, will be available at http://smrb.od.nih.gov.

    (Catalogue of Federal Domestic Assistance Program Nos. 93.14, Intramural Research Training Award; 93.22, Clinical Research Loan Repayment Program for Individuals from Disadvantaged Backgrounds; 93.232, Loan Repayment Program for Research Generally; 93.39, Academic Research Enhancement Award; 93.936, NIH Acquired Immunodeficiency Syndrome Research Loan Repayment Program; 93.187, Undergraduate Scholarship Program for Individuals from Disadvantaged Backgrounds, National Institutes of Health, HHS)

    Start Signature

    Dated: January 25, 2011.

    Jennifer S. Spaeth,

    Director, Office of Federal Advisory Committee Policy.

    End Signature End Preamble

    [FR Doc. 2011-2190 Filed 1-31-11; 8:45 am]

    BILLING CODE 4140-01-P